Please login to the form below

Not currently logged in
Email:
Password:

neurodegenerative disorders

This page shows the latest neurodegenerative disorders news and features for those working in and with pharma, biotech and healthcare.

FDA will maintain the pace, vows Woodcock, but warns of skills gap

FDA will maintain the pace, vows Woodcock, but warns of skills gap

She was able to reveal that a division focused on neuroscience will operate within the ODES to review novel therapies for psychiatric disorders, neurodegenerative disease, pain and addiction, as this field

Latest news

More from news
Approximately 1 fully matching, plus 16 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Azafaros expands executive team with three senior hires Azafaros expands executive team with three senior hires

    Attracting these experienced and skilled executives to the management team of Azafaros is a major step for the company as our lead program AZ-3102 for neurodegenerative lysosomal storage disorders is

  • Pfizer appoints chief scientific officer Pfizer appoints chief scientific officer

    Having first joined Harvard in 1989, Dr Isacson's work in neurogenerative disorders, particularly for Parkinson's disease, has become internationally renowned with his laboratory now one of the leading academic ... Dr Mikael Dolsten, president of

  • Minoyrx Therapeutics appoints chief medical officer Minoyrx Therapeutics appoints chief medical officer

    He joins the Barcelona-based drug development company from Lupin Atlantis Holdings, where he oversaw its clinical strategy and implementation of studies in various therapeutic areas, including neurodegenerative disorders. ... Prior to this, Dr Meya was

  • Chase Pharmaceuticals appoints former Allergan president Chase Pharmaceuticals appoints former Allergan president

    As CEO, Ingram will focus on the direction of Chase Pharmaceuticals' development and commercialisation of improved treatments for neurodegenerative disorders, in particular its current work on symptomatic treatment of Alzheimer's

  • Ex-GSK CEO Jean-Pierre Garnier takes up role at Alzheon Ex-GSK CEO Jean-Pierre Garnier takes up role at Alzheon

    phase III clinical programme targeting a genetically-defined Alzheimer's disease population, and execute on our long-term strategy to bring innovative therapies to patients with neurodegenerative disorders.”.

More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics